Home › Cancro metastatico › New Mexico
Studi clinici su Cancro metastatico nello stato di New Mexico
13 studi su Cancro metastatico cercano partecipanti presso sedi nello stato di New Mexico.
Città nello stato di New Mexico
Testo ufficiale dello studio (inglese)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of New Mexico Cancer Center, Albuquerque
In reclutamentoFase 2
Tutte le età · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05564377Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- University of New Mexico Comprehensive Cancer Center, Albuquerque
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06943755Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- University of New Mexico Comprehensive Cancer Center, Albuquerque
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07222800Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- University of New Mexico Comprehensive Cancer Center, Albuquerque
- CHRISTUS St. Vincent Regional Cancer Center, Santa Fe
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07222566A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Albuquerque
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06103864Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
- New Mexico Oncology Hematology Consultants, Albuquerque
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07028489A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Optimum Clinical Research Group, Albuquerque
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213804A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- University of New Mexico Comprehensive Cancer Center, Albuquerque
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06119581Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Albuquerque
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 29 lug 2026 · NCT07044336A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Christus St Vincent Regional Medical Center, Santa Fe
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 lug 2026 · NCT06657144A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- New Mexico Oncology Hematology Consultants Ltd, Albuquerque
In reclutamentoFase 1
Età 18 e oltre · Uomini · Aggiornato il 4 feb 2026 · NCT04729114VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Presbyterian Kaseman Hospital (site 208), Albuquerque
In reclutamentoFase 1/2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 11 dic 2025 · NCT03556228SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Albuquerque
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.